Informasjon/Twitter/Artikler/Børsmeldinger
Jeg vet at mange har interesse av å følge med på utviklingen i Photocure. Og for dem som eventuelt ikke er medlem i vår Facebook gruppe skal jeg også publisere her innimellom. Dersom dere ønsker å diskutere noe av det som blir delt her kan dere gjøre det på andre tråder.
Erfaringsmessig blir enhver PHO tråd ødelagt ganske umiddelbart så jeg holder den åpen kun for lesetilgang.
Forøvrig er dere hjertelig velkommen inn i FB gruppen som nå teller hele 599 medlemmer.
Det finnes 3273 aksjonærer i Photocure så det er plass til flere i gruppen.
Starter med et lite utvalg av delingene på fb gruppen siste uken.
PS! FB gruppen har nå 785 medlemmer!, den 22.8. 30.9 har den 814. og 20.11 har den 878 medlemmer.
https://twitter.com/Cysview/status/1139565681874223105
http://santansun.com/2019/06/13/gilberts-md-anderson-center-celebrates-survivors/?fbclid=IwAR3w248nRjxHfZ8Zb1C9-FGAEJL4vIXLTMbOADei7oIoHooB4SIJUwZzcIU
https://www.youtube.com/watch?v=AQCSH005uDs&fbclid=IwAR1M0zvb7he1ikyc7U6Bor3T4Tjhf1BfLkJJmnL7myLQdFzM8CM0o-qV9M0
https://finance.yahoo.com/news/why-photocure-asa-ob-pho-120355805.html?guce_referrer=aHR0cHM6Ly90ZWtpbnZlc3Rvci5uby8&guce_referrer_sig=AQAAAN1bXZLFh3xYZBPzMKtz4JpEyTxNURdI7tWOsZyP8CcFouBFik2iBwjFLBhuAduKZ4xjJpIbGqQ7lZspb9lLvZ44wdtmZhik79grZWWYVAD5SvQ1v2rfqCbtGOH5nSHLiqcRFSlOolw2BHh2m1B-keblOZk2OMtU0Nd73tCD2OzZ&guccounter=2
https://www.sciencedirect.com/topics/medicine-and-dentistry/cystoscopy?fbclid=IwAR3W1N0UZMYb4zVQ_0X2S3G4X46NYqA53ShEqAzvTZLo7qfdDALItsApCvM
https://www.mdlinx.com/journal-summaries/urothelial-carcinoma-in-situ-blue-light/2019/06/10/7569052/?spec=urology&fbclid=IwAR2xAB2LFKvvOIHC0h2zuSOrH50pHGXCJDV5hpq_66RZlXYp6eK3QUBLMR8
https://twitter.com/PhotocureASA/status/1138507513077403649
https://www.bcan.org/wp-content/uploads/2019/06/Recurrence-and-Prevention-Transcript.pdf?fbclid=IwAR3IkuPa34ZCxtyBA5LBZRlPBQvfhtz_T3UsynZx_ARWvJ2sQChY05Aqz14
Erfaringsmessig blir enhver PHO tråd ødelagt ganske umiddelbart så jeg holder den åpen kun for lesetilgang.
Forøvrig er dere hjertelig velkommen inn i FB gruppen som nå teller hele 599 medlemmer.
Det finnes 3273 aksjonærer i Photocure så det er plass til flere i gruppen.
Starter med et lite utvalg av delingene på fb gruppen siste uken.
PS! FB gruppen har nå 785 medlemmer!, den 22.8. 30.9 har den 814. og 20.11 har den 878 medlemmer.
https://twitter.com/Cysview/status/1139565681874223105
http://santansun.com/2019/06/13/gilberts-md-anderson-center-celebrates-survivors/?fbclid=IwAR3w248nRjxHfZ8Zb1C9-FGAEJL4vIXLTMbOADei7oIoHooB4SIJUwZzcIU
https://www.youtube.com/watch?v=AQCSH005uDs&fbclid=IwAR1M0zvb7he1ikyc7U6Bor3T4Tjhf1BfLkJJmnL7myLQdFzM8CM0o-qV9M0
https://finance.yahoo.com/news/why-photocure-asa-ob-pho-120355805.html?guce_referrer=aHR0cHM6Ly90ZWtpbnZlc3Rvci5uby8&guce_referrer_sig=AQAAAN1bXZLFh3xYZBPzMKtz4JpEyTxNURdI7tWOsZyP8CcFouBFik2iBwjFLBhuAduKZ4xjJpIbGqQ7lZspb9lLvZ44wdtmZhik79grZWWYVAD5SvQ1v2rfqCbtGOH5nSHLiqcRFSlOolw2BHh2m1B-keblOZk2OMtU0Nd73tCD2OzZ&guccounter=2
https://www.sciencedirect.com/topics/medicine-and-dentistry/cystoscopy?fbclid=IwAR3W1N0UZMYb4zVQ_0X2S3G4X46NYqA53ShEqAzvTZLo7qfdDALItsApCvM
https://www.mdlinx.com/journal-summaries/urothelial-carcinoma-in-situ-blue-light/2019/06/10/7569052/?spec=urology&fbclid=IwAR2xAB2LFKvvOIHC0h2zuSOrH50pHGXCJDV5hpq_66RZlXYp6eK3QUBLMR8
https://twitter.com/PhotocureASA/status/1138507513077403649
https://www.bcan.org/wp-content/uploads/2019/06/Recurrence-and-Prevention-Transcript.pdf?fbclid=IwAR3IkuPa34ZCxtyBA5LBZRlPBQvfhtz_T3UsynZx_ARWvJ2sQChY05Aqz14
Redigert 21.01.2021 kl 09:25
Du må logge inn for å svare
Nå går det jaggu unna i USA!
Klinikk nummer 139, 140 og 141 oppført på Cysview.
Capital Health Medical Center - Hopewell
1 Capital Way Pennington, NJ 08534
Capital Health – Urology Specialists
1050 Stony Hill Road Yardley, PA 19067
Capital Health – Urology Specialists
Two Capital Way, Suite 407 Pennington, NJ 08534
Klinikk nummer 139, 140 og 141 oppført på Cysview.
Capital Health Medical Center - Hopewell
1 Capital Way Pennington, NJ 08534
Capital Health – Urology Specialists
1050 Stony Hill Road Yardley, PA 19067
Capital Health – Urology Specialists
Two Capital Way, Suite 407 Pennington, NJ 08534
Redigert 21.01.2021 kl 08:46
Du må logge inn for å svare
Redigert 21.01.2021 kl 08:46
Du må logge inn for å svare
Redigert 21.01.2021 kl 08:46
Du må logge inn for å svare
Redigert 21.01.2021 kl 08:46
Du må logge inn for å svare
Klinikk nummer 138 lagt til på Cysview.
Ronald Reagan UCLA Medical Center
The Ronald Reagan UCLA Medical Center (also commonly referred to as UCLA Medical Center or "RRMC") is a hospital located on the campus of the University of California, Los Angeles, in Westwood, Los Angeles, California, United States. It is currently ranked the 6th best hospital in the United States by U.S. News & World Report, and 1st in the West Coast.[2]
Ronald Reagan UCLA Medical Center
The Ronald Reagan UCLA Medical Center (also commonly referred to as UCLA Medical Center or "RRMC") is a hospital located on the campus of the University of California, Los Angeles, in Westwood, Los Angeles, California, United States. It is currently ranked the 6th best hospital in the United States by U.S. News & World Report, and 1st in the West Coast.[2]
Redigert 21.01.2021 kl 08:46
Du må logge inn for å svare
For bladder cancer detection, the urologists are the first in central Connecticut to use a new blue light cystoscopy technology to illuminate tumors in the bladder and identify smaller cancers earlier than ever before.
Certain tumors are hard to detect using traditional white light cystoscopy, but turn pink under the enhanced imaging provided by the blue light.
“Recurrence rates for bladder cancers are somewhere in the 50–70% range. Using blue light cystoscopy, depending on the tumor type, can reduce the risk of recurrence by about 40%, which means fewer trips to the operating room,” says Dr. Benjamin Ristau, UConn Health’s surgical director of urologic oncology.
https://twitter.com/UConn/status/1186666022692098048?s=20
Certain tumors are hard to detect using traditional white light cystoscopy, but turn pink under the enhanced imaging provided by the blue light.
“Recurrence rates for bladder cancers are somewhere in the 50–70% range. Using blue light cystoscopy, depending on the tumor type, can reduce the risk of recurrence by about 40%, which means fewer trips to the operating room,” says Dr. Benjamin Ristau, UConn Health’s surgical director of urologic oncology.
https://twitter.com/UConn/status/1186666022692098048?s=20
Redigert 21.01.2021 kl 08:46
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
"We are proud that Hexvix® / Cysview® is included in studies intending to enhance Bladder Cancer treatment for patients around the world, focusing both on reducing the patient burden and the health care resources and costs. At Photocure we strongly believe that the use of Hexvix / Cysview with flexible cystoscopes in the surveillance and treatment of patients in the outpatient/office setting will give a large number of patients access to better management of their disease", says Dan Schneider, President and CEO of Photocure.
https://photocure.com/news/siu2019_athens/
https://photocure.com/news/siu2019_athens/
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Kan det komme noe om BLC i Athen nå i ettermiddag?
Vanskelig å si, men lov å håpe.
1545-1715
📷
Instructional Course 09: Management of Non-Muscle Invasive Bladder Cancer (NMIBC) - Are We Doing the Right Thing?
Chair: Makarand Khochikar, India
At the conclusion of this activity, participants will be able to:
Have a clarity on current strategies in the treatment of NMIBC, the most common yet not appropriately addressed cancer in urologic oncology.
Makarand Khochikar, India1545-1550
Introduction
Makarand Khochikar, India1550-1605
Optimizing the First TURBT - Technique, Do's and Dont's
Mark Soloway, United States1605-1620
Are We Over Indulging in Restaging TURBT
Ashish M. Kamat, United States1620-1635
Changing Paradigm in Intravesical Therapy for NMIBC
Badrinath Konety, United States1635-1715
Challenging Cases
https://www.siu-urology.org/congress-2019/scientific-programme
Vanskelig å si, men lov å håpe.
1545-1715
📷
Instructional Course 09: Management of Non-Muscle Invasive Bladder Cancer (NMIBC) - Are We Doing the Right Thing?
Chair: Makarand Khochikar, India
At the conclusion of this activity, participants will be able to:
Have a clarity on current strategies in the treatment of NMIBC, the most common yet not appropriately addressed cancer in urologic oncology.
Makarand Khochikar, India1545-1550
Introduction
Makarand Khochikar, India1550-1605
Optimizing the First TURBT - Technique, Do's and Dont's
Mark Soloway, United States1605-1620
Are We Over Indulging in Restaging TURBT
Ashish M. Kamat, United States1620-1635
Changing Paradigm in Intravesical Therapy for NMIBC
Badrinath Konety, United States1635-1715
Challenging Cases
https://www.siu-urology.org/congress-2019/scientific-programme
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
And this is not unique to this study either. We have seen the same thing with the flexible blue light study that we did where we were looking at detection of CIS with flexible blue lights, cystoscopy in the office. And we found the same thing, that cytology was not sensitive in picking up the high-grade cancers in many, many of the cases. In fact, all the lesions that were seen with blue light alone had negative cytology. So again, this is consistent with those results.
https://www.urotoday.com/video-lectures/bladder-cancer/video/mediaitem/1540-players-brightcove-net2019-10-15-19-14-58.html
https://www.urotoday.com/video-lectures/bladder-cancer/video/mediaitem/1540-players-brightcove-net2019-10-15-19-14-58.html
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
For our in-licensed photodynamic product, Cevira®, it is actually a second-generation product. The first-generation product entered Phase II trials but was discontinued because it was not efficacious enough. The second-generation product has made improvement in design to increase its absorption, which should theoretically increase the sensitivity of the drug to photo-activation. In addition, the phototherapy device has been miniaturized so it can be implanted on the cervix. Patients can leave the hospital and remove the device easily by themselves once the treatment is completed. Importantly, the product has shown positive Phase II results, which finally gave us the confidence to invest.
https://pharmaboardroom.com/interviews/kevin-pan-ceo-asieris-china/?fbclid=IwAR2-oIWM8sEpFZOWBgpzjLOosf72ECSX7-1eq7eHZ3rOyS0Myd74z-fkcQ0
https://pharmaboardroom.com/interviews/kevin-pan-ceo-asieris-china/?fbclid=IwAR2-oIWM8sEpFZOWBgpzjLOosf72ECSX7-1eq7eHZ3rOyS0Myd74z-fkcQ0
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 137 oppført på Cysview.
Brigham and Women's Faulkner Hospital
1153 Centre St, Boston, MA 02130
Brigham and Women's Faulkner Hospital
1153 Centre St, Boston, MA 02130
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Oppdatert Topp 20.
De har totalt redusert med minus ca. 15k.
Endringer:
Frank Stave + 20k(Økt jevnt med ca 15-18k pr uke siste tre uker)
Fondsfinans - 15k
Nordnet Livsforsikring -20k
Danske Bank - 1k
https://photocure.com/investor/largest-shareholders/
De har totalt redusert med minus ca. 15k.
Endringer:
Frank Stave + 20k(Økt jevnt med ca 15-18k pr uke siste tre uker)
Fondsfinans - 15k
Nordnet Livsforsikring -20k
Danske Bank - 1k
https://photocure.com/investor/largest-shareholders/
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Sometimes when we write stories, we have no idea who is impacted; other times, we are able to bring about change that we had no way of foreseeing.
In August 2018, I wrote a feature on Alex Huang, his battle with bladder cancer and his subsequent role as an ambassador for the greater Hamilton area with Bladder Cancer Canada. He was trying to promote the local support group available to other bladder cancer patients. Not only did the article help bring in some new members, but through one of those new members, Alex learned about blue-light cystoscopy, a new technology that is showing huge promise around the world as a better way to detect, and ultimately treat, bladder cancer. Now, Alex is working to get area hospitals to commit to bringing the technology here — and once they do, he’s ready to start fundraising, and I’m ready to write the update.
https://www.sachem.ca/news-story/9632150-sachem-and-gazette-stories-that-moved-our-journalists/
In August 2018, I wrote a feature on Alex Huang, his battle with bladder cancer and his subsequent role as an ambassador for the greater Hamilton area with Bladder Cancer Canada. He was trying to promote the local support group available to other bladder cancer patients. Not only did the article help bring in some new members, but through one of those new members, Alex learned about blue-light cystoscopy, a new technology that is showing huge promise around the world as a better way to detect, and ultimately treat, bladder cancer. Now, Alex is working to get area hospitals to commit to bringing the technology here — and once they do, he’s ready to start fundraising, and I’m ready to write the update.
https://www.sachem.ca/news-story/9632150-sachem-and-gazette-stories-that-moved-our-journalists/
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 136 oppført på Cysview.
VA Long Beach Healthcare System
5901 East 7th Street Long Beach, CA 90822
VA Long Beach Healthcare System
5901 East 7th Street Long Beach, CA 90822
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1007-8497
Abstract
Background Photodynamic Diagnosis (PDD) is widely used today for the diagnosis and treatment of superficial bladder cancer. This study aimed to analyse the impact of using this technique on recurrence rate, residual tumour rate and progression-free survival.
Materials and methods We conducted this study retrospectively in our unit between 10/2014 and 02/2018. We divided our patients into 2 groups: white light group, 49 patients who underwent primary bladder tumour resection with white light transurethral resection of bladder tumour (WL-TURB), and blue light group, 49 patients treated with blue light transurethral resection of bladder tumour (BL-TURB) with PDD. Patients in both groups were followed up for one year. We collected data for tumour recurrence for the first year, 3-month and 1-year relapse-free survival and 1-year progression-free assessment pursuant to the EORTC risk classification by Sylvester 2006. Furthermore, the residual tumour rate was determined by re-TURB.
Results The following results were found independent of age, gender and histological findings: Residual tumour rate: blue light group 13.95 % vs. white light group 32.6 %, (p 0.02, OR 3.8, CI 95 % [1.17 – 12.85]).; 3-month relapse-free survival: blue light group 87.7 % vs. white light group 67.4 % (p 0.02, HR 3.18, CI 95 % [1.20 – 8.42]); 1-year relapse-free survival: blue light group 77.6 % vs. white light group 55.1 % (p 0.015, HR 2.56, CI 95 % [1.20 – 5.45]); 1-year progression-free survival: blue light group 95.9 % vs. white light group 79.6 %, p 0.03, HR 5.23, CI 95 % [1.11 – 24.53])
Conclusion The use of hexaminolevulinate significantly reduces the risk of residual tumours compared with conventional TURB. The PDD technique significantly improved 3- and 12-month recurrence-free survival, especially in low and medium-risk tumours, and 1-year progression-free survival, especially in high-risk tumours
Abstract
Background Photodynamic Diagnosis (PDD) is widely used today for the diagnosis and treatment of superficial bladder cancer. This study aimed to analyse the impact of using this technique on recurrence rate, residual tumour rate and progression-free survival.
Materials and methods We conducted this study retrospectively in our unit between 10/2014 and 02/2018. We divided our patients into 2 groups: white light group, 49 patients who underwent primary bladder tumour resection with white light transurethral resection of bladder tumour (WL-TURB), and blue light group, 49 patients treated with blue light transurethral resection of bladder tumour (BL-TURB) with PDD. Patients in both groups were followed up for one year. We collected data for tumour recurrence for the first year, 3-month and 1-year relapse-free survival and 1-year progression-free assessment pursuant to the EORTC risk classification by Sylvester 2006. Furthermore, the residual tumour rate was determined by re-TURB.
Results The following results were found independent of age, gender and histological findings: Residual tumour rate: blue light group 13.95 % vs. white light group 32.6 %, (p 0.02, OR 3.8, CI 95 % [1.17 – 12.85]).; 3-month relapse-free survival: blue light group 87.7 % vs. white light group 67.4 % (p 0.02, HR 3.18, CI 95 % [1.20 – 8.42]); 1-year relapse-free survival: blue light group 77.6 % vs. white light group 55.1 % (p 0.015, HR 2.56, CI 95 % [1.20 – 5.45]); 1-year progression-free survival: blue light group 95.9 % vs. white light group 79.6 %, p 0.03, HR 5.23, CI 95 % [1.11 – 24.53])
Conclusion The use of hexaminolevulinate significantly reduces the risk of residual tumours compared with conventional TURB. The PDD technique significantly improved 3- and 12-month recurrence-free survival, especially in low and medium-risk tumours, and 1-year progression-free survival, especially in high-risk tumours
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 135 oppført på Cysview.
Reston Hospital Center, 1850 Town Center Pkwy, Reston, VA 20190
Kan være den samme som denne, har ikke fått sjekket grundig nok enda:
AndyHagen
12.09.2019 kl 21:04
1377
Ny klinikk med BLC, Reston Hospital Center. Ikke oppført på Cysview.
https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE
Reston Hospital Center, 1850 Town Center Pkwy, Reston, VA 20190
Kan være den samme som denne, har ikke fått sjekket grundig nok enda:
AndyHagen
12.09.2019 kl 21:04
1377
Ny klinikk med BLC, Reston Hospital Center. Ikke oppført på Cysview.
https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 134 oppført på Cysview.
Prestige Medical Group 720 N. Tustin Ave, Suite 104 Santa Ana, CA 92705
Prestige Medical Group 720 N. Tustin Ave, Suite 104 Santa Ana, CA 92705
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Oppdatert Topp 20 som øker litt gjennom forrige uke.
Nordnet Liv + ca. 25k
Fondsfinans Global Helse + ca. 10k
https://photocure.com/investor/largest-shareholders/
Nordnet Liv + ca. 25k
Fondsfinans Global Helse + ca. 10k
https://photocure.com/investor/largest-shareholders/
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 133 oppført på Cysview.
St. Mary’s Medical Center
https://www.cysview.com/about/where-its-available/?locate=
St. Mary’s Medical Center
https://www.cysview.com/about/where-its-available/?locate=
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 132 oppført på Cysview.com nå.
Montrose Memorial Hospital
Montrose Memorial Hospital
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 131 oppført på Cysview.com nå.
Lahey Hospital and Medical Center
Lahey Hospital and Medical Center
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Denne er også ny og kan faktisk ikke se at denne heller er oppført på Cysview.
Her snakker vi såvidt jeg kan se også flexiskop.
"“At University Urology, patients with known or suspected bladder cancer can now undergo diagnostic procedures performed by physicians who have been specially trained in the use of this innovative technology,” Terry said. “We are also able to perform BLC and bladder biopsies in the office setting, if needed.”
https://www.usahealthsystem.com/news/university-urology-blue-light
Her snakker vi såvidt jeg kan se også flexiskop.
"“At University Urology, patients with known or suspected bladder cancer can now undergo diagnostic procedures performed by physicians who have been specially trained in the use of this innovative technology,” Terry said. “We are also able to perform BLC and bladder biopsies in the office setting, if needed.”
https://www.usahealthsystem.com/news/university-urology-blue-light
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Ny klinikk med BLC, Reston Hospital Center. Ikke oppført på Cysview.
https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE
https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Klinikk nummer 130 oppført på Cysview ikveld.
https://www.cysview.com/about/where-its-available/?locate=
https://www.cysview.com/about/where-its-available/?locate=
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare
Oppdatert Topp 20 som øker med ca. 7k totalt.
Altså små bevegelser fortsatt.
https://photocure.com/investor/largest-shareholders/
Altså små bevegelser fortsatt.
https://photocure.com/investor/largest-shareholders/
Redigert 21.01.2021 kl 06:25
Du må logge inn for å svare